Market closedNon-fractional
Vera Therapeutics/VERA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Vera Therapeutics
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Ticker
VERA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Brisbane, United States
Employees
55
Website
veratx.com
VERA Metrics
BasicAdvanced
$2B
Market cap
-
P/E ratio
-$2.05
EPS
1.11
Beta
-
Dividend rate
Price and volume
Market cap
$2B
Beta
1.11
Financial strength
Current ratio
28.63
Quick ratio
27.757
Long term debt to equity
14.421
Total debt to equity
15.065
Interest coverage (TTM)
-26.91%
Management effectiveness
Return on assets (TTM)
-20.24%
Return on equity (TTM)
-36.89%
Valuation
Price to book
5.64
Price to tangible book (TTM)
5.64
Price to free cash flow (TTM)
-16.996
Growth
Earnings per share change (TTM)
-39.85%
3-year earnings per share growth (CAGR)
-76.85%
What the Analysts think about VERA
Analyst Ratings
Majority rating from 10 analysts.
VERA Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$28M
10.55%
Profit margin
0.00%
NaN%
VERA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.46
-$0.45
-$0.60
-$0.56
-
Expected
-$0.69
-$0.53
-$0.51
-$0.53
-$0.56
Surprise
-33.65%
-15.62%
18.16%
5.66%
-
VERA News
AllArticlesVideos
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
GlobeNewsWire·1 month ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vera Therapeutics stock?
Vera Therapeutics (VERA) has a market cap of $2B as of July 27, 2024.
What is the P/E ratio for Vera Therapeutics stock?
The price to earnings (P/E) ratio for Vera Therapeutics (VERA) stock is 0 as of July 27, 2024.
Does Vera Therapeutics stock pay dividends?
No, Vera Therapeutics (VERA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Vera Therapeutics dividend payment date?
Vera Therapeutics (VERA) stock does not pay dividends to its shareholders.
What is the beta indicator for Vera Therapeutics?
Vera Therapeutics (VERA) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Vera Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.